Improved mealtime treatment of diabetes mellitus using an insulin analogue

Clinical Therapeutics

Volumn 19, Issue 1, 1997, Pages 62-72

  Anderson Jr , James H ^a   Brunelle, Rocco L ^a   Koivisto, Veikko A ^b   Trautmann, Michael E ^a   Vignati, Louis ^a   DiMarchi, Richard ^a   Cameron, D P ^c   Yeu, D K ^c   Zimmet, P ^c   Lauvaux, J P ^c   Van Gaal, L F ^c   Chiasson, J L ^c   Fettes, I M ^c   Tan, M H ^c   Toth, E L ^c   Koivisto, V A ^c   Charbonnel, B ^c   Selam, J L ^c   Haslbeck, M ^c   Schulze Schleppinghoff, B ^c   Karasik, A ^c   Hazenberg, H J ^c   Van Doom, L G ^c   Bonnici, F B ^c   Hough, S ^c   Mollentze, W F ^c   Moore, R ^c   Omar, M A ^c   Robertson, L I ^c   Van Rooyen, R J ^c   De Leiva, A ^c   Jara, A ^c   Vazquez, J A ^c   Arslanian, S ^c   Bastyr, E J ^c   Bergenstal, R M ^c   Blonde, L ^c   Boyce, P A ^c   Chase, H P ^c   Clarke, D H ^c   Davidson, J ^c   Garber, A ^c   Goldberg, R B ^c   Guthrie, R A ^c   Mayfield, R K ^c   Mengel, M C ^c   Prince, M J ^c   Reeves, M L ^c   Rosenzweig, J L ^c   Schade, D S ^c   Soeldner, J S ^c   Spencer, M L ^c   Whitehouse, F W ^c   Zimmerman, B R ^c   more..

^a ELI LILLY AND COMPANY   (United States)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c Lilly Corporate Center ^*

Author keywords

diabetes mellitus; insulin analogue; insulin lispro; insulin therapy; postprandial control

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; INSULIN DERIVATIVE; INSULIN LISPRO; ISOPHANE INSULIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MEAL; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARYNGITIS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 8244260603     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80073-2     Document Type: Article

References (35)

1. Binder C. Absorption of injected insulin: A clinical-pharmacological study. Acta Pharmacol Toxicol. 1969;27(Suppl 2): 1-84.
2. Galloway JA, Spradlin CT, Nelson RL, et al. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various mixtures. Diabetes Care. 1981;4:366-376.
3. Berger M, Cüppers HJ, Hegner H, et al. Absorption kinetics and biologic effects of subcutaneously injected insulin preparations. Diabetes Care. 1982;5:77-91.
4. Malherbe C, de Gasparo M, de Hertogh R, Hoet JJ. Circadian variations of blood sugar and plasma insulin levels in man. Diabetologia. 1969;5:397-404.
5. Eaton RP, Allen RC, Schade DS, Standefer JC. "Normal" insulin secretion: The goal of artificial insulin delivery systems? Diabetes Care. 1980;3:270-273.
6. American Diabetes Association. Clinical Practice Recommendations 1995. Position statement: Insulin administration. Diabetes Care. 1995;18(Suppl 1):29-32.
7. Lean MEJ, Ng LL, Tennison BR. Interval between insulin injection and eating in relation to blood glucose control in adult diabetics. BMJ. 1985;290:105-108.
8. Jørgensen LN, Nielsen FS. Timing of premeal insulins in diabetic patients on a multiple daily injection regimen. A questionnaire study. Diabetologia. 1990;33:A116. Abstract.
9. Brems DN, Alter LA, Beckage MJ, et al. Altering the association properties of insulin by amino acid replacement. Protein Eng. 1992;5:527-533.
10. DiMarchi RD, Chance RE, Long HB, et al. Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor I. Horm Res. 1994;41(Suppl 2):93-96.
11. Galloway JA, Chance RE. Approaches to insulin analogs. In: Marshall SM, Home PD, eds. Diabetes Ann. Vol. 8. Amsterdam: Elsevier Science BV; 1994:277-297.
12. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analog of human insulin. Diabetes. 1994;43: 396-402.
13. Brange J, Owens DR, Kang S, Vølund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care. 1990;13:923-954.
14. Kang S, Owens DR, Vora JP, Brange J. Comparison of insulin analog B9AspB27Glu and soluble human insulin in insulin-treated diabetes. Lancet. 1990;335:303-306.
15. B28) on meal-related plasma glucose excursions in type 1 diabetic subjects. Diabetes Care. 1991;14:571-577.
16. Nielsen FS, Jørgensen LN, Ipsen M, et al. Long-term comparison of human insulin analog B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen. Diabetologia, 1995;38: 592-598.
17. WHO Expert Committee on Diabetes Mellitus. Second Report. World Health Organization, Technical Report Series:646. Geneva: WHO; 1980.
18. 1c by high performance cation exchange chromatography. Clin Chem. 1980;26:3-7.
19. Hoffmeister H, Junge B. Uber die haltbarkeit von serumbestandteilen und die Zuverlassigkeit ihrer bestimmung im autoanalyzer SMA 12-30-survey. Z Klin Chem Klin Biochem. 1970;8:613-617.
20. Howey DC, Bowsher RR, Brunelle R, et al. [Lys(B28), Pro(B29)]-human insulin: Effect of injection time on postprandial glycemia. Clin Pharmacol Ther. 1995;58: 459-469.
21. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. NEJM. 1993;329:977-986.
22. Wang PH, Lau J, Chalmers TC. Metaanalysis of effects of intensive blood glucose control on late complications of type I diabetes. Lancet. 1993;341:1306-1309.
23. Reichard P, Nilsson B-Y, Rosenquist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. NEJM. 1993;329:304-309.
24. Stephenson J, Fuller JH, on behalf of the EURODIAB IDDM Complications Study Group. Microvascular and acute complications in IDDM patients: The EURODIAB IDDM Complications Study. Diabetologia. 1994;37:278-285.
25. Krolewski AS, Laffel LMB, Krolewski M, et al. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. NEJM. 1995;332:1251-1255.
26. Uusitupa MIJ, Niskanen LK, Siitonen O, et al. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in Type 2 (non-insulin-dependent) diabetic and nondiabetic subjects. Diabetologia. 1993;36: 1175-1184.
27. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes. 1994;43: 960-967.
28. Kinmonth AL, Baum JD. Timing of prebreakfast insulin injection and postprandial metabolic control in diabetic children. BMJ. 1980;280:604-606.
29. Letiexhe MR, Rutters A, Schmitt H. (Lys(B28), Pro(B29)) human insulin: Patients treated with lyspro vs human regular insulin: Quality of life assessment. Diabetologia. 1994;37(Suppl 1):A168. Abstract.
30. Torlone E, Pampanelli S, Lalli C, et al. Postprandial glycaemic control in IDDM after s.c. LYS, PRO insulin analogue or human regular insulin. Diabetes. 1995;44 (Suppl 1):71A. Abstract.
31. Ceriello A, Giacomello R, Stel G, et al. Hyperglycemia-induced thrombin formation in diabetes: The possible role of oxidative stress. Diabetes. 1996;44:924-928.
32. Ceriello A, Taboga C, Tonutti L, et al. Post-meal coagulation activation in diabetes mellitus: The effect of acarbose. Diabetologia. 1996;39:469-473.
33. Fineberg SE, Fineberg NS, Anderson JH, et al. Comparative immunogenicity of LysPro (B28, 29) human insulin analog between type I and type II patients. Diabetologia. 1994;37(Suppl 1):A168. Abstract.
34. Buelke-Sam J, Byrd RA, Hoyt JA, Zimmermann JL. A reproductive and developmental toxicity study in CD rats of LY275585, [Lys(B28),Pro(B29)]-human insulin. J Am Coll Toxicol. 1994;13: 247-260.
35. Slicker LJ, Brooke GS, Chance RE, et al. Insulin and IGF-I analogs: Novel approaches to improved insulin pharmacokinetics. In: Leroith D, Raizada MK, eds. Current Directions in Insulin-Like Growth Factor Research. New York: Plenum Press; 1994:25-32.